Vadadustat FDA：Akebia says FDA will give its once
Akebia says FDA will give its once
2023年5月30日—TheFDArejectedvadadustatbecauseoftheriskofheartproblemsaswellasdrug-inducedliverdamage.Duringtheappealprocess,thecompany ...。其他文章還包含有：「Afterhigh」、「AkebiaproposesnewdosingfororalanemiadrugamidFDA...」、「AkebiaTherapeuticsCompletedTypeAMeetingwiththeFDA...」、「FDAProvidesAkebiaTherapeuticsaPath...」、「FDAProvidesAkebiaTherapeuticsaPathForwardfor...」、「FDA拒絕批准...
查看更多 離開網站
After high
https://www.fiercepharma.com
Akebia plans to resubmit its application for vadadustat for anemia due to chronic kidney disease in adult patients on dialysis by the end of the ...
Akebia proposes new dosing for oral anemia drug amid FDA ...
https://www.fiercepharma.com
Vadadustat belongs to an emerging class of drugs known as HIF-PHI. The class once bore high hopes as potentially convenient alternatives to ESAs ...
Akebia Therapeutics Completed Type A Meeting with the FDA ...
https://www.prnewswire.com
Vadadustat is approved in Europe for the treatment of symptomatic anemia due to CKD in adult patients on chronic maintenance dialysis. In Japan, ...
FDA Provides Akebia Therapeutics a Path ...
https://www.biospace.com
Vadadustat is approved in Europe for the treatment of symptomatic anemia due to CKD in adult patients on chronic maintenance dialysis. In Japan, ...
FDA Provides Akebia Therapeutics a Path Forward for ...
https://ir.akebia.com
Vadadustat is approved in Europe for the treatment of symptomatic anemia due to CKD in adult patients on chronic maintenance dialysis. In Japan ...
FDA 拒絕批准貧血藥物Vadadustat，Akebia 大規模裁員
https://geneonline.news
美國食品藥物管理局（FDA）因為安全問題近期拒絕批准美國生物製藥公司Akebia Therapeutics 用於治療慢性腎病引起的貧血藥物Vadadustat，因其增加了 ...
Press Release
https://ir.akebia.com
Vadadustat is an investigational new drug and is not approved by the U.S. Food and Drug Administration (FDA). On March 29, 2022 , the FDA issued a complete ...
《FDA》不服慢性腎病貧血藥物Vadadustat藥證申請遭拒 ...
http://www.genetinfo.com
Akebia Therapeutics旗下治療慢性腎病貧血藥物Vadadustat因安全性問題於今年3月遭FDA拒絕新藥申請(NDA)，公司近日已向FDA提出正式爭議解決需求(FDRR) ...
《FDA》安全問題! 美國FDA 拒絕批准Akebia 慢性腎病貧血藥 ...
http://www.genetinfo.com
據了解，在該試驗中，雖然使用vadadustat 的患者比使用對比藥物的患者出現了更多的血栓栓塞事件，但總體事件發生率是相同的─ 都是6.6 人/100 患者年( ...